| Year |
Citation |
Score |
| 2004 |
Shao W, Keeton EK, McDonnell DP, Brown M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proceedings of the National Academy of Sciences of the United States of America. 101: 11599-604. PMID 15289619 DOI: 10.1073/Pnas.0402997101 |
0.359 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2011 |
Keeton E, Palakurthi S, Alimzhanov M, Grondine M, Chen Y, Brown J, McEachern K, Cao Y, Chinnappan D, Shen M, Dakin L, Zheng X, Lamb M, Wu A, Chen H, et al. AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia Blood. 118: 1540-1540. DOI: 10.1182/BLOOD.V118.21.1540.1540 |
0.217 |
|
| 2005 |
Keeton EK, Brown M. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Molecular Endocrinology (Baltimore, Md.). 19: 1543-54. PMID 15802375 DOI: 10.1210/Me.2004-0395 |
0.197 |
|
| 2007 |
Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Molecular Cell. 27: 380-92. PMID 17679089 DOI: 10.1016/J.Molcel.2007.05.041 |
0.193 |
|
| 2006 |
Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, et al. Genome-wide analysis of estrogen receptor binding sites. Nature Genetics. 38: 1289-97. PMID 17013392 DOI: 10.1038/Ng1901 |
0.189 |
|
| 2014 |
Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur S, Wang S, Chen Y, Wu A, Shen M, Gibbons FD, Lamb ML, Zheng X, Stone RM, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 123: 905-13. PMID 24363397 DOI: 10.1182/Blood-2013-04-495366 |
0.151 |
|
| 2007 |
Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Research. 67: 6477-83. PMID 17616709 DOI: 10.1158/0008-5472.Can-07-0746 |
0.129 |
|
| 2015 |
Kirschner AN, Wang J, van der Meer R, Anderson PD, Franco-Coronel OE, Kushner MH, Everett JH, Hameed O, Keeton EK, Ahdesmaki M, Grosskurth SE, Huszar D, Abdulkadir SA. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. Journal of the National Cancer Institute. 107. PMID 25505253 DOI: 10.1093/Jnci/Dju407 |
0.1 |
|
| 2016 |
Tron AE, Keeton EK, Ye M, Casas-Selves M, Chen H, Dillman KS, Gale RE, Stengel C, Zinda M, Linch DC, Lai Z, Khwaja A, Huszar D. Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208. Leukemia & Lymphoma. 1-3. PMID 27189703 DOI: 10.3109/10428194.2016.1171861 |
0.098 |
|
| 2002 |
Keeton EK, Fletcher TM, Baumann CT, Hager GL, Smith CL. Glucocorticoid receptor domain requirements for chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter in different nucleoprotein contexts. The Journal of Biological Chemistry. 277: 28247-55. PMID 12029095 DOI: 10.1074/Jbc.M203898200 |
0.072 |
|
| 2012 |
Dakin LA, Block MH, Chen H, Code E, Dowling JE, Feng X, Ferguson AD, Green I, Hird AW, Howard T, Keeton EK, Lamb ML, Lyne PD, Pollard H, Read J, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorganic & Medicinal Chemistry Letters. 22: 4599-604. PMID 22727640 DOI: 10.1016/J.Bmcl.2012.05.098 |
0.068 |
|
| 2004 |
Keeton EK, Brown M. Coregulator expression and breast cancer: improving the predictive power of estrogen receptor alpha. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1229-30. PMID 12684386 |
0.068 |
|
| 2022 |
Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton EK, Wang P, Gupta D, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecologic Oncology. PMID 35690498 DOI: 10.1016/j.ygyno.2022.05.020 |
0.046 |
|
| 2012 |
Gibbons F, McEachern K, Keeton E, Huszar D. 536 Determining the Likelihood of Achieving Clinical Proof-of-Mechanism (PoM) with AZD1208 From Preclinical Efficacy Studies Using PK/PD Modelling European Journal of Cancer. 48: 165. DOI: 10.1016/S0959-8049(12)72333-X |
0.013 |
|
| Hide low-probability matches. |